Outset Medical, Inc.
OM- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001484612
In the last 90 days, Outset Medical, Inc. insiders filed 1 open-market purchase and 2 sales; 76 institutions reported holding it in 13F filings for Q3 2026, worth $36.7M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:16 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $81.7M (68.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 6, 2025 | Jan 8, 2024 | Jan 9, 2023 | Feb 16, 2022 |
| Revenue | $119.5M | $113.7M | $130.4M | $115.4M | $102.6M |
| Cost of revenue | $72.7M | $75.1M | $101.4M | $97.5M | $95.0M |
| Gross profit | $46.8M | $38.6M | $29.0M | $17.8M | $7.61M |
| Operating expenses | $113.5M | $151.9M | $198.8M | $178.9M | $138.1M |
| Research and development | $21.2M | $38.4M | $57.3M | $48.9M | $36.7M |
| Selling, general and administrative | $37.9M | $43.5M | $45.2M | $40.5M | $36.3M |
| Operating income | -$66.7M | -$113.4M | -$169.8M | -$161.0M | -$130.5M |
| Interest expense | $14.0M | $23.9M | $12.7M | $3.57M | $1.72M |
| Income tax | $718.0K | $491.0K | $523.0K | $295.0K | $199.0K |
| Net income | -$81.7M | -$128.0M | -$172.8M | -$163.0M | -$131.9M |
| EPS, basic | $-5.37 | $-2.46 | $-3.48 | $-3.38 | – |
| EPS, diluted | $-5.37 | $-2.46 | $-3.48 | $-3.38 | – |
| Weighted shares, basic | 15.2K | 52.0K | 49.6K | 48.2K | – |
| Weighted shares, diluted | 15.2K | 52.0K | 49.6K | 48.2K | – |
| Margins and growth | |||||
| Gross margin | 39.1% | 33.9% | 22.2% | 15.5% | 7.4% |
| Operating margin | -55.8% | -99.7% | -130.2% | -139.6% | -127.2% |
| Net margin | -68.3% | -112.6% | -132.5% | -141.2% | -128.6% |
| Revenue growth, year over year | +5.1% | −12.8% | +13.0% | +12.4% | +105.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 6, 2025 | Jan 8, 2024 | Jan 9, 2023 | Feb 16, 2022 |
| Cash and equivalents | $35.0M | $124.0M | $68.5M | $73.2M | $182.3M |
| Short-term investments | $133.9M | $34.7M | $134.8M | $214.3M | $157.1M |
| Accounts receivable | $28.3M | $35.6M | $33.0M | $28.1M | $25.6M |
| Inventory | $47.6M | $59.4M | $49.2M | $51.5M | $39.2M |
| Total current assets | $250.9M | $258.2M | $291.2M | $373.6M | $409.8M |
| Property, plant and equipment | $4.67M | $8.13M | $13.3M | $15.9M | $13.0M |
| Total assets | $264.5M | $275.8M | $313.8M | $400.1M | $463.5M |
| Accounts payable | $554.0K | $3.86M | $5.83M | $603.0K | $1.76M |
| Short-term debt | – | – | – | $4.75M | $2.02M |
| Total current liabilities | $37.6M | $45.4M | $55.3M | $51.9M | $51.7M |
| Long-term debt | $96.2M | $197.4M | $130.1M | $96.3M | $29.8M |
| Total liabilities | $137.5M | $249.0M | $190.9M | $154.1M | $89.4M |
| Shareholders' equity | $127.0M | $26.8M | $122.9M | $246.0M | $374.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 6, 2025 | Jan 8, 2024 | Jan 9, 2023 | Feb 16, 2022 |
| Operating cash flow | -$46.3M | -$116.3M | -$131.4M | -$145.7M | -$130.3M |
| Capital expenditures | $798.0K | $912.0K | $3.44M | $8.32M | $3.11M |
| Free cash flow | -$47.1M | -$117.2M | -$134.8M | -$154.1M | -$133.4M |
| Depreciation and amortization | $4.34M | $5.73M | $5.81M | $5.17M | $5.16M |
| Stock-based compensation | $15.6M | $29.4M | $38.6M | $27.2M | $17.4M |
| Investing cash flow | -$97.7M | $103.9M | $83.0M | -$66.3M | -$142.5M |
| Financing cash flow | $55.5M | $67.9M | $43.7M | $72.9M | $160.1M |
| Net change in cash | -$88.5M | $55.5M | -$4.70M | -$139.1M | -$112.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 13.1% | 25.8% | 29.6% | 23.6% | 17.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 18.9M | +4.0% | SEC |
| Aug 4, 2026 | 18.8M | +5.8% | SEC |
| May 1, 2026 | 18.5M | +4.6% | SEC |
| Feb 6, 2026 | 18.3M | −66.0% | SEC |
| Nov 6, 2025 | 18.2M | −65.5% | SEC |
| Aug 1, 2025 | 17.8M | −65.9% | SEC |
| May 2, 2025 | 17.7M | −65.7% | SEC |
| Feb 24, 2025 | 53.9M | +6.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q1 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.